KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Vir Biotechnology (VIR) Deferred Taxes (2018 - 2024)

Vir Biotechnology's Deferred Taxes history spans 3 years, with the latest figure at -$2.6 million for Q4 2024.

On a quarterly basis, Deferred Taxes fell 148.64% to -$2.6 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$3.6 million, a N/A change, with the full-year FY2024 number at -$2.9 million, down 177.42% from a year prior.
Deferred Taxes hit -$2.6 million in Q4 2024 for Vir Biotechnology, down from $57000.0 in the prior quarter.
Over the last five years, Deferred Taxes for VIR hit a ceiling of $57000.0 in Q3 2024 and a floor of -$2.6 million in Q4 2024.